ClinicalTrials.gg
Not yet recruitingNCT06222021NETTUNOUpdated Jan 24, 2024

Hyperlactacidemia in Major Abdominal Surgery and Monocarboxylate Receptors

An interventional study of Genetic analysis of polymorphism of membrane receptors involved in lactate transport in Surgical Procedure, Unspecified, Postoperative Complications and Hyperlactatemia, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-24.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Not applicable, Interventional, and Screening

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
109
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to identify those situations in which the increase of lactate levels is not clinically relevant since it is associated with altered genetic polymorphism of the genes involved in the membrane proteins acting as carriers for lactate (mainly monocarboxylate transporters, MCTs) patients undergoing major abdominal surgery.

The main questions it aims to answer are:

  1. Is there a relationship between the lactate levels in the immediate post-operative period and the presence of some lactate receptor polymorphisms?
  2. Can hyperlactacidemia related to lactate receptor polymorphisms affect length of stay in the recovery room and/or in intensive care unit, postoperative hospital stay, postoperative complications? - Which are the risk factors for hyperlactacidemia in the immediate post-operative period in addition to the presence of lactate receptors polymorphisms?

Participants will undergo pre-operative genomic assay testing.

Read the detailed description

Lactic acidosis is traditionally attributed to cellular hypoxia, to an imbalance between the body's demand for oxygen and its availability. Lactate is produced by the muscles, skin, brain, red blood cells and intestine and eliminated by the liver and kidneys. Lactate is produced by the following biochemical reaction: Pyruvate + reduced nicotinamide adenine dinucleotide (NADH) + H+ ↔ Lactate + nicotinamide-adenine dinucleotide (NAD+). Under normal conditions, this reaction produces lactate from pyruvate in a ratio of 10 to 1. Pyruvate comes from glycolysis and is used by mitochondria. When glycolysis is increased or mitochondrial oxidative phosphorylation is blocked, pyruvate accumulates and is converted into lactate generating hyperlactacidemia and acidosis. Normal lactate levels are 0-2 mmol/L. Hyperlactacidemia, usually defined as values above 2.2 mmol/L, is divided into two types: A (associated with hypoxia) and B (related to increased stress-induced aerobic metabolism, mitochondrial diseases and the use of drugs such as metformin and beta2 agonists). The lactate/pyruvate ratio allows us to distinguish the two types of hyperlactacidemia. In hyperlactacidemia type A, this ratio is >10 while in type B it remains constant (L/P=10). In case of liver dysfunction, hyperlactacidemia may be associated with a variable L/P ratio based on the determining cause reduction in lactate clearance. In fact, lactate extraction may depend on the hepatic blood flow, the polymorphism of some genes involved in the lactate transport (mainly MCT1) and the potential of hydrogen (pH) which inhibits gluconeogenesis when lower than 7.10. Since lactic acid is an hydrophilic weak acid, its transport across membranes requires transporters that belong to the transporter family monocarboxylates (MCTs) encoded by the solute carrier family 16 (SLC16) gene family. It has been demonstrated that the MCT1 (rs1049434) T1470A polymorphism is associated with a deficit in the transmembrane transport of lactate: in fact, the T allele is correlated with an approximately 50% reduction in the lactate transport rate compared to the A6 allele. MCT4, which has a very low affinity for pyruvate and a greater affinity for lactate, ensures that pyruvate is converted into lactate before transmembrane transport. Polymorphisms affecting these receptors can influence the different speed of transmembrane lactate flow and therefore correlate with lesser or greater accumulation of serum lactate. Another membrane receptor involved in lactate transport has recently been described: G-coupled protein receptor 81 (GPR81), present in adipocytes. Polymorphisms affecting the gene encoding this receptor could correlate with a different accumulation of lactate. An increase in the level of lactates is often correlated with increased morbidity and mortality in critical situations critical such as sepsis, trauma, major cardiac and abdominal surgery. Measurement of perioperative biomarkers such as lactate is often used in clinical practice as an outcome predictor. However, there are no studies aimed to identify those situations in which the increase of lactates is not clinically relevant since it is associated with altered genetic polymorphism.

The investigators hypothesized that lactate levels at 3 hours after the end of major abdominal surgery will be higher in the patients carrying the T allele versus the A allele for MCT1 gene.

02

Conditions studied

  • Surgical Procedure, Unspecified
  • Postoperative Complications
  • Hyperlactatemia
  • Abdomen Disease
03

In context

Postoperative Complications

1,332 studies on the registry are indexed under Postoperative Complications; 311 are open to participants now.

This study's planned enrollment of 109 is close to the median of 114 across 766 interventional studies indexed under Postoperative Complications.

Browse Postoperative Complications studies →

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 952 studies on the registry; 541 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Indication for elective major abdominal surgery

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • Liver cirrhosis
  • Liver surgery
  • Intraoperative chemotherapy
  • Previous gastric bypass surgery (thiamine deficiency)
  • Severe cardiovascular/respiratory impairment
  • Mitochondrial diseases
  • Pheochromocytoma
  • Chronic renal failure ≥ stage III
  • Refusal to sign the
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
109 participants (estimated)

Study arms

  • Other
    Genetic analysis of polymorphisms of membrane receptors involved in lactate transport

    Before the start of surgery, after arterial line cannulation, a blood sample will be collected in an ethylenediaminetetraacetic acid (EDTA) test tube for genetic analysis of polymorphisms of membrane receptors involved in lactate transport including transporter family monocarboxylates 1 (MTC1), transporter family monocarboxylates 4 (MTC4) and Gi-coupled protein receptor 81 (GPR81).

    Genetic: Genetic analysis of polymorphism of membrane receptors involved in lactate transport

Interventions

  • GeneticGenetic analysis of polymorphism of membrane receptors involved in lactate transport

    The DNA extracted from the blood samples (through extractor MagCore) will then undergo gene sequencing by Sanger sequencing and/or Custom NGS (Next Generation Sequencing) panels and will be used to identify nucleotide variants within genes involved in lactate transport (MCT-1/4, GPR81).

06

What researchers measure

Primary outcomes

  1. Lactate levels

    Lactate levels (mmol/L) in the patients carrying the T allele versus the A allele for MCT1 gene.

    Time frame: 3 hours after the end of surgery

Secondary outcomes

  1. Polymorphisms of lactate receptors (presence of MCT4 and GPR8)

    Prevalence of the lactate receptors MCT4 and GPR8 polymorphisms throughout the genetic analysis of a blood sample.

    Time frame: Minutes and an average of 30 minutes before the start of surgery

  2. Lactate clearance

    Evaluation of the association between lactate clearance (lactate levels at the end of surgery - lactate levels at 3 hours after the end of surgery)x100/lactate levels at the end of surgery and the presence of lactate receptor polymorphisms (MCT4 and GPR8).

    Time frame: 3 hours after the end of surgery

  3. Lactate clearance

    Evaluation of the association between lactate clearance (lactate levels at the end of surgery - lactate levels at 24 hours after the end of surgery)x100/lactate levels at the end of surgery and the presence of lactate receptor polymorphisms (MCT4 and GPR8).

    Time frame: 24 hours after the end of surgery

  4. Postoperative recovery

    Length of stay in recovery room (RR) or in intensive care (ICU)

    Time frame: Hours (RR) or days (ICU) and average of three hours for RR and one day in ICU

  5. In-hospital stay

    Hospital stay duration

    Time frame: Days until discharge, an average of 7 day

  6. Hyperlactacidemia

    Analysis of potential risk factors for hyperlactacidemia (lactate levels \>2.2 mmol/L) as well as the presence of lactate receptor polymorphisms including age (years), comorbidities, American Society of Anesthesiologists (ASA) physical status classification system, Body Mass Index (kg/m2), type and duration of surgery (hours), surgical approach (open, laparoscopic, robotic), total of liquids administered (ml), total diuresis (ml), blood losses (ml), intraoperative blood components transfusions (units), blood gas analyses parameters, number of hypotensive episodes during surgery (MAP\<65 mmHg) requiring the administration of norepinephrine or its dosage increase.

    Time frame: 3 hours after the end of surgery

07

Study locations

1 site
  • UOC Anestesia delle Chirurgie Generali e dei Trapianti, Fondazione Policlinico Universitario A. Gemelli IRCCS
    Rome, Italy/Lazio 00168, Italy
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06222021
Responsible party
Sponsor
First posted
Jan 24, 2024
Start date
Feb 2024 (estimated)
Primary completion
Aug 2025 (estimated)
Completion
Oct 2025 (estimated)
Last update
Jan 24, 2024

Study contacts

Paola Aceto, MD
Contact
paola.aceto@policlinicogemelli.it
00390630154507
Chiara Cambise, MD
Contact
chiara.cambise@policlinicogemelli.it
00390630154507

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion